These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17632316)

  • 21. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD; Ewald N
    Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyruvate kinase type tumor M2 in urological malignancies.
    Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
    Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
    Gold DV; Modrak DE; Ying Z; Cardillo TM; Sharkey RM; Goldenberg DM
    J Clin Oncol; 2006 Jan; 24(2):252-8. PubMed ID: 16344318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM; Gerstmeier F; Sauer-Eppel H; Sapoutzis N; Wechsel HW
    Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F; Fischer G; Eigenbrodt E
    Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
    Guan M; Tong Y; Liu X; Dong D; Zhou Y
    Ann Clin Lab Sci; 2017 Nov; 47(6):676-686. PubMed ID: 29263041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
    Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
    Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer.
    Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH
    Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel type of CA19-9 carrier in human bile and sera of cancer patients: an implication of the involvement in nonsecretory exocytosis.
    Uozumi N; Gao C; Yoshioka T; Nakano M; Moriwaki K; Nakagawa T; Masuda T; Tanabe M; Miyoshi E
    J Proteome Res; 2010 Dec; 9(12):6345-53. PubMed ID: 20954701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor M2-pyruvate kinase in stool as a biomarker for diagnosis of colorectal cancer: A meta-analysis.
    Huang JX; Zhou Y; Wang CH; Yuan WW; Zhang ZD; Zhang XF
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C225-8. PubMed ID: 25450288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E; Basenau D; Holthusen S; Mazurek S; Fischer G
    Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.